A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential research setting.
Opioid use disorder is a public health problem that has contributed to unprecedented levels of overdose deaths. Detoxification – or medically supervised withdrawal – is a widely used treatment for opioid use disorder. However, failing to adequately manage opioid withdrawal symptoms can contribute to people leaving treatment.
Clonidine and buprenorphine are two medications widely used to manage opioid withdrawal. Tramadol hydrochloride is a promising alternative option for effective opioid use disorder treatment, according to the article.
Full story of tramadol and opioid withdrawal at Science Daily
Inadequate access to opioid addiction treatment programs has led to a thriving black market for Suboxone, the drug that helps patients overcome their addiction, experts tell The Wall Street Journal.
More than 36,000 doctors are certified in the United States to prescribe Suboxone and other buprenorphine-based medications. Until last year, those doctors were limited to prescribing the drugs to 100 patients each. Last year, the Obama Administration increased that number to 275, and began allowing physician assistants and nurse practitioners to prescribe the drugs.
Full story of Suboxone thriving on the black market at drugfree.org
Only 27 percent of youths treated for opioid addiction receive buprenorphine or naltrexone, known as medication-assisted treatment, a new study finds.
“These medications are considered the evidence-based standard of care for opioid addiction by the American Academy of Pediatrics,” said lead researcher Dr. Scott Hadland of Boston University School of Medicine.
Buprenorphine (sold as Suboxone) has been shown to reduce cravings, while naltrexone (sold as Revia and Vivitrol) blocks the high from opioids, HealthDay reports.
Full story of opioid addiction and medicated-assisted treatment at drugfree.org
Only one in four young adults and teens with opioid use disorder (OUD) are receiving potentially life-saving medications for addiction treatment, according to a new Boston Medical Center (BMC) study published online in JAMA Pediatrics.
Buprenorphine and naltrexone are medications used to treat OUD that help prevent relapse and overdose when used appropriately. In late 2016, the American Academy of Pediatrics recommended, for the first time, that providers offer medication treatment to adolescents with OUD.
Prior studies have shown that among all adults in treatment for opioids, one-third started using opioids before age 18, and two-thirds started before age 25. Unlike methadone, buprenorphine and naltrexone can be offered in the primary care setting. However, few teens receive medication due, in part, to a widespread shortage of physicians who have received a waiver certification required to prescribe buprenorphine. And, as researchers note, of all of the physicians who are certified in the United States, only one-percent are pediatricians.
Full story of treating young people with opioid use disorder at drugfree.org
Health and Human Services Secretary Tom Price’s description of medication-assisted treatment for addiction as “substituting one opioid for another” is inaccurate, according to addiction experts who have asked Price to “set the record straight.”
A letter to Price signed by almost 700 researchers and practitioners notes there is a substantial body of research showing that methadone and buprenorphine, also known as medication-assisted treatment, are effective in treating opioid addiction. These medications, which are opioids, have been the standard of care for addiction treatment for years, they wrote.
Full story of Tom Price’s description of medication-assisted treatment at drugfree.org